Partnered Content

As pressure mounts to cut costs, reduce environmental impact, and accelerate development, pharmaceutical innovators are rethinking how medicines are made. A new generation of technologies—flow chemistry, biocatalysis, high-throughput experimentation (HTE), and advanced automation—is reshaping the fu

Discover how FDA’s C3TI is advancing clinical trials and creating new opportunities to shape the future of drug development.

Discover how FDA’s C3TI is advancing clinical trials and creating new opportunities to shape the future of drug development.

Neurodiversity in the workplace reflects varied cognitive profiles, including conditions like autism, ADHD, and dyslexia. Aspire Pharma outlines steps to support neurodivergent employees, such as flexible work, clear communication, training for manager, and employee-led groups that promote inclusion

Cell and gene therapy sponsors are increasingly faced with hard decisions focused around mitigating potential delays.

Blending Human Experts With AI Agents Cuts Costs, Increases Access, And Improves Customer Experience

Almost 50% of biopharma are con-sidering China for clinical studies because of vast patient pools, competitive approval pathways, and cost savings.

Oncology continues to lead the way as a therapeutic focus for the pharma industry.

CGTs are among the fastest-growing areas in therapeutics - explore the key strategies driving long-term commercial success across the entire product lifecycle.

Access key takeaways from a roundtable on the evolving landscape for rAAV-based gene therapies. Experts discussed approaches to clinical development, regulatory barriers, and the future outlook for AAV developers and lab services organizations.

Expert panelists discuss regulatory challenges, flexible approaches to assay selection, and applying scientific reasoning with guidelines to address immunogenicity and safety assessment challenges in oncology biologics and biosimilars.

Stay current with trends in infectious disease clinical trials, with fresh insights from a recent roundtable event. Discover how the landscape is evolving and what to expect in the future, with key takeaways from industry experts.

Computer systems validation (CSV) has long been a regulatory necessity but is considered time and resource-consuming to execute.

In recent years, global regulatory requirements have evolved in many areas of the MedTech product life cycle management.

Despite widespread recognition of the importance of diversity in clinical trials, most trials still fail to recruit diverse participants.

Fourier-transform infrared (FTIR) spectroscopy is one of the most common forms of infrared spectroscopy and one of the most popular analytical techniques for quality assurance (QA), quality control (QC), and materials identification in the pharmaceutical industry.

Key opinion leaders share their perspectives on how transformative technologies like AI will significantly impact the biopharma industry in 2025.

Discover how transforming field reps from “Wild Cards” to “Masters of the Message” in Pharma Omnichannel Marketing, enhances performance and mitigates risk.

Discover what’s on the horizon for the pharma industry as truly transformative technologies revolutionize the way drugs are developed, delivered and manufactured.

With the pharmaceutical industry still adjusting to the potential impacts of Humira's loss of exclusivity, another milestone for biosimilars has been achieved in 2022.

Learn more about how China’s biopharmas are going global by working with dependable and trustworthy companion diagnostics partners.

Cell and gene therapies (CGTs) are continuing to gain momentum in life sciences globally.

Catalytic hydrogenation is a proven green manufacturing process that can transform the synthesis of active pharmaceutical ingredients (API), driving down costs while reducing environmental impact.

The use of mRNA in modern therapeutics is growing in popularity and efficacy.

Gain exclusive insights into the biggest challenges biotechs face in oncology and uncover the latest opportunities to accelerate drug development.

Hematological oncology is a growing area of the global pharmaceutical pipeline, meaning more treatments in research and development are set to reach Phase I and II clinical studies.

With delays currently facing drug developers due to some contract manufacturing organizations (CMOs) experiencing backlogs, future expectations for these service providers are being redefined.

As the immuno-oncology landscape evolves, developers are facing new challenges in early-phase design, differentiation, and regulatory alignment — all while advancing increasingly complex modalities.

As in vivo CAR-T therapy nears clinical use, researchers and industry leaders explore how it could transform autoimmune disease treatment. Novotech’s Pete Robinson joins Citeline’s Meredith Landry to discuss the science, strategy, and partnerships shaping the future of cell therapy.

As in vivo CAR-T therapy nears clinical use, researchers and industry leaders explore how it could transform autoimmune disease treatment. Novotech’s Pete Robinson joins Citeline’s Meredith Landry to discuss the science, strategy, and partnerships shaping the future of cell therapy.

Hear experts Matthieu Culié and Alessandro Agosti as they discuss how Olon stands out in a competitive landscape through its fully integrated end-to-end ADC manufacturing expertise, global operations, impurity control and strategic facilities.

Watch now as Adalvo CEO Anil Okay shares with Citeline his perspectives on the rapidly-growing European B2B’s recent acquisition by private equity firm EQT. Find out what it means for the business, and how it may reflect wider pharma trends, in this insightful video interview.

ICROM on Flexibility, HPAPIs, and the Future of CDMO Services

Lonza is addressing the growing global demand for biologics by utilizing its expert teams and the advanced capabilities of its newly acquired large-scale manufacturing site in Vacaville, California. Joanna McCafferty, Director of Commercial Development, shares more in this brief video. Ask ChatG

Biotechs focus on novel cancer therapies to address the rising global burden. Yet, oncology R&D poses unique, complex challenges. Overcoming these while adapting to an evolving landscape is key to transforming patient care and improving outcomes.